Browse the evidence

Semaglutide and tirzepatide resolve metabolic dysfunction-associated steatohepatitis (MASH) in 41% and 53% of patients, respectively, without worsening fibrosis after 52-72 weeks.

These medications can significantly improve liver health in adults with MASH.

Phentermine/topiramate ER treatment improved glucose regulation, lipid profiles, and decreased blood pressure.

The treatment may enhance metabolic health in obese patients.

Lean mass constituted 25%–39% of total weight lost with incretin agonists: semaglutide (35.2%), tirzepatide (25.4%), and liraglutide (26.8%).

Incretin therapies can lead to significant lean mass loss during weight reduction.

Lifestyle interventions showed comparable proportional lean mass loss (26.2%) to incretin therapies (p = 0.42 for comparison).

Lifestyle interventions can be as effective as incretin therapies in preserving lean mass during weight loss.

Efsubaglutide Alfa showed a preferable tolerability and safety profile.

Efsubaglutide Alfa may be a safer option for weight management compared to other treatments.

NAFLD is a risk factor for atherosclerotic cardiovascular disease.

Clinicians should consider NAFLD when assessing cardiovascular risk in patients.

Resolution of steatohepatitis without worsening of fibrosis occurred in 62.9% of the patients in the semaglutide group compared to 34.3% in the placebo group.

Semaglutide may be an effective treatment option for improving liver histology in patients with MASH.

In the 15-mg tirzepatide group, 62% of participants achieved resolution of MASH without worsening of fibrosis compared to 10% in the placebo group (difference of 53 percentage points; P<0.001).

Tirzepatide may be an effective treatment option for patients with MASH and moderate to severe fibrosis.

Weight gain during adulthood was associated with significantly increased risk of major chronic diseases.

Practitioners should counsel patients on the risks associated with weight gain throughout adulthood.

Weight gain is linked to increased incidence of type 2 diabetes and hypertension.

Monitoring weight gain may be essential for preventing chronic diseases like diabetes and hypertension.

Obesity was associated with an increased risk of early-onset colorectal cancer (CRC) among women, with a multivariable relative risk (RR) of 1.93 for obese women (BMI ≥30.0).

Practitioners should consider obesity as a significant risk factor for early-onset CRC in women.

Weight gain since 18 years of age is associated with an increased risk of early-onset CRC, with a RR of 2.15 for women gaining 40.0 kg or more.

Monitoring weight gain in young women may help in early CRC risk assessment.

Prediabetes is associated with increased risk of diabetes, cardiovascular events, and mortality.

Healthcare providers should monitor and manage prediabetes to reduce risks of diabetes and cardiovascular events.

Metformin decreased the risk of diabetes among individuals with prediabetes by 3.2 cases per 100 person-years during 3 years.

Metformin can be an effective option for certain individuals at risk of diabetes.

Obesity contributes to poor health outcomes, reduced quality of life, and over 2.8 million deaths each year.

Healthcare providers should prioritize obesity management to improve health outcomes.

People living with overweight/obesity are at greater risk for cardiovascular morbidity and mortality.

Clinicians should assess cardiovascular risk in patients with obesity.

GLP-1 RA use is associated with increased risk of gallbladder or biliary diseases for longer durations (RR, 1.40; 95% CI, 1.26-1.56) compared to shorter durations (RR, 0.79; 95% CI, 0.48-1.31).

Clinicians should monitor patients on GLP-1 RAs for gallbladder issues, especially with prolonged use.

Metabolic surgery is effective for producing sustained weight loss and treating hypertension in patients with severe obesity.

Metabolic surgery should be considered as a viable treatment option for severe obesity and associated hypertension.

Obesity has been declared a disease that results in impaired quality of life and reduced life expectancy.

Healthcare practitioners should recognize obesity as a disease and address its impact on patients' quality of life.

Two-thirds of obesity-related excess mortality is attributable to cardiovascular disease.

Efforts to reduce obesity should be prioritized to decrease cardiovascular disease mortality.

Obesity is underrecognized and sub-optimally addressed compared to other modifiable cardiovascular risk factors.

Clinicians should enhance their focus on obesity as a critical cardiovascular risk factor.

At 7 years, HbA1c decreased by 1.6% in the bariatric surgery group compared to a decrease of 0.2% in the medical/lifestyle management group.

Bariatric surgery may lead to significantly better long-term glycemic control compared to medical management.

Diabetes remission rates were higher in the bariatric surgery group, with 18.2% achieving remission at 7 years compared to 6.2% in the medical/lifestyle group.

Bariatric surgery may significantly increase the likelihood of diabetes remission compared to medical management.

1-year reinitiation was lower for those without type 2 diabetes (36.3%) compared with those with type 2 diabetes (47.3%).

Practitioners should note that patients without type 2 diabetes may have lower rates of reinitiating GLP-1 RA therapy.